AVITA Medical (RCEL) Expected to Announce Earnings on Thursday

AVITA Medical (NASDAQ:RCEL) is projected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

AVITA Medical (NASDAQ:RCEL) last issued its earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). The company had revenue of $18.41 million for the quarter, compared to the consensus estimate of $18.40 million. AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AVITA Medical Price Performance

RCEL stock opened at $9.49 on Wednesday. AVITA Medical has a 1 year low of $7.51 and a 1 year high of $18.93. The stock has a market capitalization of $248.81 million, a PE ratio of -3.97 and a beta of 1.55. The company’s 50-day moving average is $10.28 and its 200-day moving average is $10.68. The company has a debt-to-equity ratio of 9.39, a current ratio of 2.83 and a quick ratio of 2.47.

Wall Street Analysts Forecast Growth

A number of analysts have commented on RCEL shares. Lake Street Capital decreased their price target on shares of AVITA Medical from $20.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price target on shares of AVITA Medical in a report on Tuesday, December 24th. D. Boral Capital dropped their target price on shares of AVITA Medical from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Finally, Piper Sandler reiterated a “neutral” rating and set a $12.00 price target (up from $9.00) on shares of AVITA Medical in a report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Insider Activity at AVITA Medical

In other news, Director Robert Mcnamara purchased 10,000 shares of the stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $10.09 per share, with a total value of $100,900.00. Following the completion of the acquisition, the director now owns 45,749 shares in the company, valued at $461,607.41. This represents a 27.97 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have acquired 12,461 shares of company stock worth $129,689. 1.82% of the stock is owned by corporate insiders.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.